SequelSEC

TuHURA Biosciences, Inc./NV HURA

Pharmaceutical Preparations · CIK 0001498382 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
-$27.71M
Fiscal year ended 2025-12-31

TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and net income of -$30.05M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from TuHURA Biosciences, Inc./NV’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

TuHURA Biosciences, Inc./NV income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Revenue$0$0$0
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailable
Net income-$30.05M-$21.68M-$29.32M
Research & development$20.53M$13.34M$9.40M
Weighted-average diluted sharesshares 47.93Mshares 18.66Mshares 11.89M
Pretax income-$30.05M-$21.68M$29.30M
Income tax expense$1.60K$3.77K$0
Diluted EPS$-0.63$-1.21$-2.47
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$7.58M$3.87M$4.14M
Selling & marketingUnavailableUnavailableUnavailable

Balance

TuHURA Biosciences, Inc./NV balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$3.62M$12.66M$3.67M
Total assets$27.35M$19.97M$4.36M
Current assets$4.62M$19.61M$4.16M
Total liabilities$6.42M$5.37M$5.92M
Current liabilities$5.92M$5.33M$3.60M
Total equity incl. NCI$20.93M$14.59M-$1.56M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
Goodwill$10.74MUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$3.77M$3.15M$1.87M

Cash flow

TuHURA Biosciences, Inc./NV cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$27.63M-$14.73M-$11.95M
Capital expenditures$76.08K$57.91K$79.22K
Investing cash flow-$1.34M-$6.05M-$1.30M
Financing cash flow$19.93M$29.77M$2.66M
Net change in cash-$9.04M$8.99M-$10.59M
Stock-based compensation$6.42M$1.96M$478.89K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$24.75K
Depreciation & amortization$71.26K$116.71K$177.38K

Derived

TuHURA Biosciences, Inc./NV derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$27.71M-$14.79M-$12.03M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.78x3.68x1.16x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable0.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.